Aberrant proteolytic digestion of biglycan and decorin by saliva and exocrine gland lysates from the NOD mouse model for autoimmune exocrinopathy

Clinical and Experimental Rheumatology

Volumn 18, Issue 2, 2000, Pages 233-240

  Yamachika, S ^a   Brayer, J ^a   Oxford, G E ^a   Peck, A B ^a   Humphreys Beher, M G ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Exocrine glands; Extracellular matrix proteins; Proteases; Sjogren's syndrome

Indexed keywords

BIGLYCAN; DECORIN;

ANIMAL MODEL; ARTICLE; CELL LYSATE; CONTROLLED STUDY; EXOCRINE GLAND; EXTRACELLULAR MATRIX; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SALIVA; SJOEGREN SYNDROME;

ANIMALS; AUTOIMMUNE DISEASES; BLOTTING, WESTERN; DIABETES MELLITUS, TYPE 2; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; PROTEOGLYCANS; RECOMBINANT PROTEINS; SALIVA; SALIVARY GLANDS; SEVERE COMBINED IMMUNODEFICIENCY; SIALADENITIS; SJOGREN'S SYNDROME; TRANSFORMING GROWTH FACTOR BETA;

EID: 0034076326     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. FITCH J, LINSENMAYER T: Interstitial basement membrane component in development. In YURCHENCO P, BIRK O and MECHAM R (Eds.): Extracellular Matrix Assembly and Structure. New York, Academic Press 1994: 441.
2. BERNFIELD MR, BANERJEE SD, KODA J, RAPRAGER AC: Remodeling of the basement membrane: Morphogenesis and maturation. In PORTER R and WHELAN J (Eds.): Basement Membranes and Cell Movement. UK, Pittman Press 1984: 172.
3. BIRKEDAL-HANSEN H, MOORE WGI, BODDEN MK et al.: Matrix metalloproteinases: A review. Crit Rev Oral Biol Med 1993;4:197-251.
4. AZUMA M, TAMATANI T, YUKI T et al.: Increased matrix metalloproteinase-2 activity induced by TGF-β1 in duct cells of human salivary gland is associated with the development of cyst formation in vivo. J Oral Pathol Med 1996; 25: 467-73.
5. LIN S, CHIANG C, HONG C et al.: Immunolocalization of interstitial collagenase (MMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in radicular cysts. J Oral Pathol Med 1997; 26: 458-63.
6. CHANDLER S, MILLER KM, CLEMENTS JM et al.: Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: An overview. J Neuroimmunol 1997; 72: 155-61.
7. TALAL N: Sjögren's syndrome: historical overview and clinical spectrum of disease. Rheum Dis Clin North Am 1992; 18: 507-16.
8. FOX RI, KANG H-I: Pathogenesis of Sjögren's syndrome. Rheum Dis Clin North Am 1992; 18: 517-38.
9. KONTTINEN YT, KANGASPUNTA P, LINDY O et al.: Collagenase in Sjögren's syndrome. Ann Rheum Dis 1994; 53: 836-9.
10. AZUMA M, MOTEGI K, AOTA K et al.: Role of cytokines in the destruction of acinar structure in Sjögren's syndrome salivary glands. Lab Invest 1997; 77: 269-80.
11. FOX P, SPEIGHT P: Current concepts of autoimmune exocrinopathy: Immunologic mechanisms in the salivary pathology of Sjögren's syndrome. Crit Rev Oral Biol Med 1996; 7: 144-58.
12. KONG L, OGAWA N, NAKABAYASHI T et al.: Fas and Fas ligand expression in the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 1997; 40: 87-97.
13. WU AJ, LAFRENIE RM, PARK C et al.: Modulation of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) by interferon-gamma in a human salivary gland cell line. J Cell Physiol 1997; 171: 117-24.
14. BLACK RA, RAUCH CT, KOZLOSKY CJ et al.: A metalloproteinase disintegrin that releases tumour necrosis factor-alpha from cells. Nature 1997; 385: 729-31.
15. BOUMBA D, SKOPOULI FN, MOUTSOPOULOS HM: Cytokine mRNA expression in the labial salivary tissues from patients with Sjögren's syndrome. Br J Rheumatol 1995; 34: 326-33.
16. KIZU Y, SAKURAI H, KATAGIRI S et al.: Immunohistological analysis of tumor growth factor beta 1 expression in normal and inflamed salivary glands. J Clin Pathol 1996;49: 728-32.
17. OHYAMA Y, NAKAMURA S, MATSUZAKI G et al.: Cytokine messenger RNA expression in the labial salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 1996; 39: 1376-84.
18. OGAWA N, DANG H, LAZARIDIS K et al.: Analysis of transforming growth factor beta and other cytokines in autoimmune exocrinopathy (Sjögren's syndrome). J Interferon Cytokine Res 1995; 15: 759-67.
19. CHANDRASEKAR B, MCGUFF HS, AUFDERMORTE TB et al.: Effects of calorie restriction on transforming growth factor β1 and proinflammatory cytokines in murine Sjögren's syndrome. Clin Immunol Immunopathol 1995; 76: 291-6.
20. DANG H, GEISER AG, LETTERIO JJ et al.: SLE-like autoantibodies and Sjögren's syndrome-like lymphoproliferationin TGF-beta knockout mice. J Immunol 1995; 155: 3205-12.
21. NAKABAYASHI T, LETTERIO JJ, GEISER AG et al.: Up-regulation of cytokine mRNA, adhesion molecule proteins, and MHC class II proteins in salivary glands of TGF-beta knockout mice: MHC class II is a factor in the pathogenesis of TGF-beta knockout mice. J Immunol 1997; 158: 5527-35.
22. GOETINCK PF: Proteoglycans in development. In BODE HR (Ed.): Current Topics in Developmental Biology, Vol. 25. San Diego, Academic Press 1991: 111.
23. YAMAGUCHI Y, MANN DM, RUOSLAHTI E: Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature 1990; 346: 281-4.
24. IOZZO RV: Matrix proteoglycans: From molecular design to cellular function. Annu Rev Biochem 1998; 67: 609-52.
25. CS-SZABÓ G, ROUGHLEY PJ, PLAAS AHK et al.: Large and small proteoglycans of osteoarthritic and rheumatoid articular cartilage. Arthritis Rheum 1995; 38: 660-8.
26. WHISCH-PREHM P, MIEHLKE R, KRESSE H: Presence of small proteoglycan fragments in normal and arthritic human cartilage. Arthritis Rheum 1992; 35: 1042-52.
27. KURODA K, SHINKAI H: Gene expression in types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 1997; 289: 567-72.
28. IMAI K, HIRAMATSU A, FUKUSHIMA D et al.: Degradation of decorin by matrix metalloproteinases: Indication of the cleavage sites, kinetic analyses and transforming growth factor-β1 release. Biochem J 1997; 322: 809-14.
29. YAMACHIKA S, NANNI JM, NGUYEN H-KT et al.: Excessive synthesis of matrix metalloproteinases in the exocrine tissues of the NOD mouse models for Sjögren's syndrome. J Rheumatol 1998; 25: 2371-80.
30. ROBINSON CP, YAMACHIKA S, ALFORD CE et al.: Elevated levels of cysteine protease activity in saliva and salivary glands of the nonobese diabetic (NOD) mouse model for Sjögren syndrome. Proc Natl Acad Sci USA 1997; 94: 5767-71.
31. KONTTENIN YT, HALINEN S, HANEMAAIJER R et al.: Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogenesis of Sjögren's syndrome. Matrix Biol 1998; 17: 335-47.
32. ROBINSON CP, YAMAMOTO H, PECK AB et al.: Genetically programmed development of salivary gland abnormalities in the NOD (non-obese diabetic)-scid mouse in the absence of detectable lymphocytic infiltration: A potential trigger for sialoadenitis in NOD mice. Clin Immunol Immunopathol 1996; 79: 50-9.
33. ROBINSON CP, YAMACHIKA S, BOUNOUS DI et al.: A novel NOD-derived murine model of primary Sjögren's syndrome. Arthritis Rheum 1998; 41: 150-6.
34. MOSCATELLO DK, SANTRA M, MANN DM et al.: Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest 1998; 101: 406-12.
35. HOCKING AM, STRUGNELL RA, RAMAMURTH Y P et al. : Eukaryotic expression of recombinant biglycan. Post-translational processing and the importance of secondary structure for biological activity. J Biol Chem 1996; 271: 19571-7.
36. HU Y, NAKAGAWA Y, PURUSHOTHAM KR, HUMPHREYS-BEHER MG: Functional changes in salivary glands of autoimmune disease-prone NOD mice. Am J Physiol 1992; 263: E607-14.
37. BRADFORD MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
38. LAEMMLI UK: Cleavage of structual proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
39. TOWBIN H, STAEHLIN T, GORDON J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 1979; 78: 4350-4.
40. ROBINSON CP, CORNELIUS J, BOUNOUS DI et al.: Characterization of the changing lymphocyte populations and cytokine expression in the exocrine tissues of autoimmune NOD mice. Autoimmunity 1998; 27: 29-44
41. DEIORIO FC: Descriptive statistics. In: SASS Applications Programming: A Gentle Introduction. Boston, PWS-Kent Publishing Co. 1991: 87.
42. GIRI SN, HYDE DM, BRAUN RK et al.: Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis. Biochem Pharmacol 1997; 54: 1205-16.
43. HILDEBRAND A, ROMARIS M, RASMUSSEN LM et al.: Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J 1994; 302: 527-34.
44. SVENSSON L, HEINEGARD D, OLDBERG A: Decorin-binding sites for collagen type I are mainly located in leucine-rich repeats 4-5. J Biol Chem 1995; 270: 20712-6.
45. KAMADA A, TAMURA I, OKAZAKI J et al.: Characteristics and localization of rat submandibular gland proteoglycans. Archs Oral Biol 1996; 41: 951-8.
46. MARTI HP, LEE L, KASHGARIAN M, LOVETT DH: Transforming growth factor-β1 stimulates glomerular mesangial cell synthesis of the 72-kD type IV collagenase. Am J Pathol 1994; 144: 82-94.
47. KOSKI H, KONTTINEN YT, GU X-H, HIETANEN J, MALMSTRÖM M: Transforming growth factor β2 in labial salivary glands in Sjögren's syndrome. Ann Rheum Dis 1995; 54: 744-7.
48. SCHÖNHERR E, HAUSSER H, BEAVAN L et al.: Decorin-type I collagen interaction; presence of separate core protein binding domains. J Biol Chem 1995; 270: 8877-83.